Make the profile of
DrugPatentWatch yours.

Company description

DrugPatentWatch is a biopharmaceutical intelligence platform that provides data on drug patents, pipelines, litigation, pricing, and global market opportunities. Updated daily and covering more than 134 countries, the platform serves pharmaceutical companies, generic manufacturers, healthcare systems, and other life sciences organisations seeking direct access to primary source data on drug patent status, generic entry timing, and competitive market dynamics. The platform has been cited by CNN, the New England Journal of Medicine, Nature journals, Reuters, Bloomberg, and FiercePharma, and draws clients from more than 70 countries.

DrugPatentWatch positions itself as an alternative to traditional analyst reports by pulling data directly from primary sources — including the USPTO, FDA Orange Book, ANDA filings, patent litigation records, and patent registers across 134 countries — and making that data available continuously without editorial delay or intermediary interpretation. The platform has been operating for more than 20 years and offers data exports that users retain permanently, independent of their subscription status.

Core Platform Capabilities

• Patent Litigation Intelligence: Provides access to full complaints and court documents, and allows users to study failed patent challenges to inform litigation strategy and anticipate early generic entry.
• Generic Entry Opportunities: Identifies drugs with expiring or expired patents to support portfolio decisions, due diligence, and tracking of investigational compounds at various development stages.
• Global Drug Patents: Covers branded and generic market opportunities across 134 countries, including identification of markets where competitors have weak or absent patent protection.
• Market Entry Strategy: Provides historic sales figures, buyer power assessments, and reimbursement segmentation data to support market potential evaluation and distribution planning.
• AI Research Assistant: A deep research engine that aggregates information from multiple sources and provides answers with full citations.
• Automated Reports and Dashboards: Allows users to automate monitoring processes, configure custom alerts, and receive targeted intelligence updates.

Data Access and Methodology

• All drug profiles are refreshed daily from primary sources, with no editorial lag or publication cycle delays.
• Users can query raw data according to their own analytical requirements and modify queries as strategy evolves.
• Full datasets can be exported in structured formats and are retained by the user permanently, including after a subscription ends.
• The platform draws from the same primary sources — USPTO, FDA Orange Book, ANDA filings, litigation records, and international patent registers — that third-party analysts use, but makes them directly accessible to subscribers.

Pricing and Positioning

• DrugPatentWatch offers monthly subscription plans, described as a fraction of the cost of boutique pharma intelligence firms, which the platform notes typically charge between $20,000 and $100,000 or more per engagement.
• A free trial is available, with multiple plan tiers offered.
• The platform is rated 4.3 out of 5 on G2 and 4.4 out of 5 on Crozdesk based on user reviews.

Notable Use Cases and Customer Feedback

• Users include senior analysts at generic pharmaceutical companies, procurement directors at North American healthcare systems, and organisations in Latin America seeking access to information on expired and protected patents in the US and internationally.
• Reported use cases include identifying potential competitors based on NDAs, patents, and clinical trial references; tracking patent expiry timelines to align vendor relationships; and monitoring drugs approaching generic entry, such as Keytruda (pembrolizumab, 2028), Eliquis (apixaban, 2026), and Ozempic (semaglutide, 2032).

DrugPatentWatch is designed for organisations that require continuous, direct access to pharmaceutical patent and market data without relying on periodic analyst reports, offering a self-service model in which users form their own analytical conclusions from primary source material.

AI-generated · replace with your own

Software attributed to DrugPatentWatch

• DrugPatentWatchView

Edit all with premium access